Companiesandmarkets.com

China prostatic hyperplasia drugs market: CNY 3.6 billion industry in 2012

Press Release   •   Feb 25, 2013 17:23 GMT

The China prostatic hyperplasia drugs market is estimated to have reached a value of around CNY 3.67 billion in 2012. This would suggest year-on-year growth of 12.6%

Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.

In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.

Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc.

Four drug varieties, namely, Finasteride, Tamsulosin, Doxazosin and Cernilton dominate China's hospital-use anti-PH drug market. In 2011, it controlled nearly 80% of hospital-use anti-PH drug market nationwide.

There are numerous anti-PH drug manufacturers in China. In 2011, the total market share of top 4 manufacturers of China's hospital-use anti-PH drugs by market share was 71.22%, which was slightly lower than that in 2010; the total market share of top 8 manufacturers was over 83%, with the highly-concentrated market. Among it, Sino-US Hangzhou MSD Pharmaceutical Co., Ltd. ranked the top, accounting for over 30% of the market share in 2011. Its primary variety is Finasteride (Proscar), accounting for over 90% of the market share in the drug variety. Developed by MSD Co., Ltd, Finasteride (Proscar) appeared in domestic market in 1993 and always tops the BPH drug market.

All in all, the competition pattern of China's anti-PH drug market will not largely change on the whole in recent years. The overall hospital-use market is continuously leaded by Finasteride, Tamsulosin, Doxazosin and Cernilton. Meanwhile, drugs at low to medium prices are hard to contend against giants. Even though varieties are characterized by excellent qualities and cheap prices, they can only become local brands.

In the coming years, a large group of branded drugs will successively lose patent protection, which is a great opportunity for non-patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China's anti-PH drug market is very bright. The annual growth rate of China's anti-PH drug market size is predicted to be over 10% in years to come.

For more information on the China prostatic hyperplasia drugs market market, please click here: China prostatic hyperplasia drugs market

For more information on the Healthcare and Medical market, please click here: Healthcare and Medical Reports

Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.